ImmunoPrecise Antibodies reports LENSai Immunogenicity Screening study results

ImmunoPrecise Antibodies (IPA) announced results of a newly expanded study demonstrating that its LENSai Immunogenicity Screening can reliably predict Anti-Drug-Antibody risk for therapeutic proteins before they enter animal studies or human trials. “ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,” said Dr. Jennifer Bath, President & CEO, IPA. “With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.”